secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0000886163-23-000004
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ligand Q4 revenue $50.4M, net loss $14.5M; raises 2023 guidance on royalties and EPS
--------------------------------------------------------------------------------

- Q4 total revenues $50.4M (down 11% YoY); royalties $22.0M (up 25% YoY); net loss from continuing ops $14.5M ($0.86 per share).
- Full year 2022 total revenues $196.2M (down 19% YoY); adjusted net income $82.2M ($4.79 per diluted share) vs $108.0M ($6.27) in 2021.
- 2023 guidance raised: royalties $74-78M (prev $72-76M), total revenue $120-124M, adjusted diluted EPS $3.30-3.45 (prev $3.10-3.30).
- Travere's FILSPARI received FDA accelerated approval for IgA nephropathy; Verona positive Phase 3 for ensifentrine in COPD.
- OmniAb spin-out completed Nov 1, 2022; cash and investments $211.9M at year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616323000004/0000886163-23-000004-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616323000004/lgnd-20230222.htm
  HTML page:      https://secwatch.observer/filing/0000886163-23-000004

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer